KINAXO Biotechnologies and Roche Diagnostics have entered into a new collaboration to develop new treatments using phosphoproteomics to identify new disease biomarkers.

Under the agreement Kinaxo will use its phosphoproteomics technology PhosphoScout to support the identification of biomarkers related to new treatment approaches based on therapeutic antibodies under development at Roche.

PhosphoScout is a quantitative phosphoproteomics service tailored to examine cellular signal transduction pathways and their response to drug treatment. The technology is based on proprietary mass spectrometry methods, which enable the analysis of 15,000 phosphorylation sites in a single experiment.

Kinaxo CSO Dr Klaus Godl said that cellular signal transmission in eukaryotic cells is mainly regulated by the reversible phosphorylation of proteins.

“Therefore, differential analysis of the complete cellular phosphoproteome on drug treatment provides highly informative insights into the modes of action of targeted cancer drugs,” Godl said.

Financial details of the agreement were not disclosed.